跳到正文
原文
Medical Xpress·· 2026-10-14精选AI 评分65

JAMA Neurology:%p-tau217 与脑淀粉样蛋白的关联在各种族人群中基本一致

Alzheimer's blood biomarker tracks brain amyloid similarly across racial groups, study finds

AI 导读

一项纳入 15,612 名 55 至 80 岁认知未受损成人的全球研究显示,血液标志物 %p-tau217 水平与 PET 测得的脑淀粉样蛋白之间的关联在各种族群体中基本一致。

推荐理由

研究覆盖四大洲1.5万余名筛查者,为血液标志物在不同种族人群中作为初筛工具提供了一致性证据。

正文
Alzheimer
Credit: SHVETS production from Pexels

A large global study provides new evidence supporting the use of blood biomarkers in an Alzheimer's clinical trial to screen for elevated brain amyloid levels among potential participants who are cognitively unimpaired. The findings, published in JAMA Neurology, show that the relationship between blood biomarker levels and brain amyloid was largely similar across racial groups.

The study also revealed that levels of the biomarker were generally lower among Asian and Black participants compared with white participants, and among Hispanic participants compared with non-Hispanic participants. These differences raise questions about the factors that influence blood biomarker levels and how they relate to dementia risk across populations.

Treatments such as lecanemab can slow cognitive decline in people with early symptomatic Alzheimer's disease by targeting amyloid buildup in the brain. Clinical trials are now testing whether these drugs can delay cognitive decline in cognitively unimpaired individuals with elevated amyloid if taken before symptoms begin.

To help identify participants for these trials, researchers use a blood test that measures the proportion of a protein fragment carrying a specific Alzheimer's-related modification, known as %p-tau217. The blood test helps identify individuals who are more likely to have elevated brain amyloid, which is then confirmed in the study with a positron emission tomography (PET) scan.

Because people from some populations have been historically underrepresented in these trials, researchers have sought to better understand how blood biomarkers relate to brain amyloid across different groups.

"We found that %p-tau217 levels were lower in populations that have historically been underrepresented in clinical trials. Importantly, however, the relationship between the biomarker and brain amyloid was generally consistent across racial groups," said Doris P. Molina-Henry, Ph.D., the study's corresponding author and associate professor of research neurology with the Epstein Family Alzheimer's Therapeutic Research Institute at the Keck School of Medicine of USC.

"This supports the use of blood-based biomarkers as an initial screening tool for elevated amyloid in a preclinical Alzheimer's disease trial."

Linking %p-tau217 to genetic risk

The study included data from 15,612 adults ages 55 to 80, collected at 106 research sites across Asia, Australia, Europe and North America. Participants were cognitively unimpaired and undergoing screening for the AHEAD 3-45 trials, which are testing lecanemab in people with certain levels of amyloid in the brain but no symptoms of Alzheimer's disease. Participants underwent blood-based screening before eligible individuals proceeded to additional assessments, including PET scans.

Although %p-tau217 levels differed across racial and ethnic groups, the marker showed similar relationships with Alzheimer's-related measures across racial groups. Across the groups studied, higher %p-tau217 levels were consistently associated with higher levels of brain amyloid measured on PET scans.

The study also found that carriers of the APOE ε4 variant, a major genetic risk factor for Alzheimer's, generally had higher levels of %p-tau217 than adults without the variant—a pattern that largely held across racial and ethnic groups.

"These findings reinforce the relationship between APOE ε4 and Alzheimer's-related blood biomarkers, while showing that the strength of this relationship can vary across populations," Molina-Henry said.

Other causes of dementia

The findings also raise broader questions about dementia risk. Although Asian, Black and Hispanic participants had lower levels of the Alzheimer's-related blood biomarker, prior research reports that Black and Hispanic groups have historically faced a higher overall risk of developing dementia.

"These findings remind us that dementia risk is complex and may involve multiple contributing factors beyond Alzheimer's-related changes measured by this blood test or a PET scan," Molina-Henry said. "Other processes in the brain may also play a role—and that warrants further study."

The Alzheimer's Plasma Extension Study, or APEX, is following individuals who underwent AHEAD 3-45 screening but did not meet the amyloid eligibility criteria for the trials. By continuing to collect blood tests, PET scans and measures of cognition, the study will help researchers understand how these trajectories change over time in this group.

"Following these individuals over time will help us understand how Alzheimer's-related biomarkers change and how those changes relate to brain amyloid and cognition," Molina-Henry said.

Publication details

Doris P. Molina-Henry et al., Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease, JAMA Neurology (2026). DOI: 10.1001/jamaneurol.2026.3598

Journal information: Archives of Neurology

Who's behind this story?

Swati Mestri

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Alzheimer's blood biomarker tracks brain amyloid similarly across racial groups, study finds (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-alzheimer-blood-biomarker-tracks-brain.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com